# A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding

> **NCT03476928** · PHASE3 · TERMINATED · sponsor: **Bayer** · enrollment: 153 (actual)

## Conditions studied

- Uterine Fibroids and Heavy Menstrual Bleeding

## Interventions

- **DRUG:** Vilaprisan (BAY1002670)

## Key facts

- **NCT ID:** NCT03476928
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-30
- **Primary completion:** 2021-07-12
- **Final completion:** 2021-07-12
- **Target enrollment:** 153 (ACTUAL)
- **Why stopped:** Due to a change in the development program, the study was closed prematurely.
- **Last updated:** 2022-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03476928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03476928, "A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03476928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*